Kyverna Therapeutics has secured four presentations at the American Academy of Neurology Annual Meeting April 18–22, 2026 in Chicago, including two late-breaking oral sessions and two poster sessions. Oral presentations will feature primary analysis from the pivotal KYSA-8 trial and updated Phase 2 data from KYSA-6.

The KYSA-8 multicenter Phase 2 registrational trial in stiff person syndrome demonstrated statistically significant improvements across all primary and secondary endpoints, including reversal of progressive disability. These topline results build on previous positive data and support miv-cel’s potential as a first-in-class therapy for this rare autoimmune disorder.

The open-label, single-arm Phase 2 portion of the KYSA-6 trial in generalized myasthenia gravis will present updated efficacy and safety data for the CD19-targeting CAR T-cell therapy. The analysis aims to show durable, drug-free remission potential following a single administration of miv-cel.

Poster sessions will cover a real-world natural history study on timed 25-foot walk outcomes in stiff person syndrome and the design of a global, randomized Phase 3 study comparing KYV-101 to standard-of-care immunosuppression in myasthenia gravis. These programs outline the strategic path toward regulatory submission and broader clinical adoption.